Kissei Pharmaceutical. has filed a patent for a method to reduce menstrual blood loss in patients with uterine fibroids using a specific compound. The method involves administering the compound in specified doses to achieve the desired effect. GlobalData’s report on Kissei Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kissei Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kissei Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Kissei Pharmaceutical's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Reducing menstrual blood loss using gnrh antagonist compound

Source: United States Patent and Trademark Office (USPTO). Credit: Kissei Pharmaceutical Co Ltd

A recently filed patent (Publication Number: US20240000785A1) outlines a method for reducing menstrual blood loss in female human patients by administering a specific compound in either 100 mg or 200 mg doses per day. The compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxpenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, is targeted towards patients with uterine fibroids. The administration can be oral and once daily, with the option of using a choline salt as the pharmaceutically acceptable salt.

Furthermore, the patent also covers a method for treating uterine fibroids in female patients by administering the same compound in 100 mg or 200 mg doses per day. The compound can be in the form of a pharmaceutically acceptable salt, specifically a choline salt, and can be administered orally once daily. Additionally, a kit is described in the patent, containing the compound in unit dosage forms of either 100 mg or 200 mg, along with a package insert instructing users on how to perform the method outlined in the patent claims. The kit also includes the option of using the compound in the form of a choline salt as a pharmaceutically acceptable salt.

To know more about GlobalData’s detailed insights on Kissei Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies